ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in transforming the life for organ transplant patients, by allowing the complete discontinuation of all immunosuppression treatment and restoration of a normal life.
ITBMed total Funding
ITBMed latest funding size
Time since last funding
|3 years ago|
Who are ITBMed key executives?
ITBMed's key executives are Pablo Legorreta, Jan Ståhlberg and David Berglund.
Who are ITBMed competitors?
Competitors of ITBMed include Cantabio Pharmaceuticals, Novartis and Rigel Pharmaceuticals.
Where is ITBMed headquarters?
ITBMed headquarters is located at Sonja Kovalevskys Gata 4, Stockholm.
Where are ITBMed offices?
ITBMed has offices in Stockholm and New York.
How many offices does ITBMed have?
ITBMed has 2 offices.
Receive alerts for 300+ data fields across thousands of companies